

YH/SE/09/2025-26

May 26, 2025

The Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5th Floor, Plot No. C/1  
G Block, Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051, India

Symbol: YATHARTH  
ISIN: INE0JO301016

Dept. of Listing Operations  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001, India

Scrip Code: 543950  
ISIN: INE0JO301016

**Subject: Outcome of Board Meeting**

Dear Sir/Madam,

This is to inform you that, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. on May 26, 2025, inter-alia, has approved the Audited Financial Results (Standalone and Consolidated) of the Company for the fourth quarter and financial year ended March 31, 2025. The said financial results along with Audit Reports and Unmodified opinion on Audited Financial Results (Consolidated and Standalone) are enclosed;

The above information will also be made available on website of the Company at <https://www.yatharthhospitals.com/investors>

The Board Meeting commenced at 12:30 PM and concluded at 2:16 PM.

This is for your kind information and records.

Thanking You

Yours Faithfully,  
For Yatharth Hospital and Trauma Care Services Limited

**Ritesh Mishra**  
Company Secretary & Compliance Officer  
M. No.: A51166

Encl.:A/a

**Registered Office**

JA-108, DLF Tower A, Jasola District Centre, New Delhi - 110025  
Tel: 011-49967892

**Our Hospitals**

📍 Sector 110, Noida, Uttar Pradesh-201304  
📍 Sector Omega -01, Greater Noida, Uttar Pradesh-201308



**R. NAGPAL ASSOCIATES**  
CHARTERED ACCOUNTANTS

B-1/1018, VASANT KUNJ,  
NEW DELHI - 110 070  
TELEPHONE : 011-41082626  
EMAIL : rohit\_mehra@rnaca.in  
rnaca1@gmail.com

**Independent Auditor's Report On Annual Audited Ind AS Standalone Financial Results of Yatharth Hospital & Trauma Care Services Limited for the quarter and year ended March 31, 2025 pursuant to Regulations 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited

Report on the Audit of Standalone Financial Results

We have audited the accompanying statement containing the Annual Standalone Audited financial results of **Yatharth Hospital & Trauma Care Services Limited** for the Quarter and year ended 31st March, 2025 together with the notes thereon (hereinafter referred to as "the Statement") being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement

(i) is presented in accordance with the requirements of Regulations 33 of the Listing Regulations; and

(ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the total comprehensive income (comprising of profit and other comprehensive income) and other financial information of the Company for the Quarter and year ended March 31, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in Auditor's Responsibilities for the Audit of the statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



## **Responsibilities of the Management and Those Charged with Governance for this Statement**

This accompanying Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared on the basis of the related Standalone annual financial statement. The Board of Directors of the company are responsible for the preparation and presentation of the statement that give a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (IND AS) prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the accompanying Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process of the Company.

## **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on complete set of financial statement on whether the company has adequate internal financial control with reference to financial statement in place and the operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Annual Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statements, including the disclosures, and whether the statements represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude or misstatements in the Annual standalone Financial Results that individually or In aggregate, makes it probable that the economic decision of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We Consider quantitative materiality and qualitative factors (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matters**

Attention is drawn to the fact that the figures for the quarter ended 31<sup>st</sup> March 2025 and 31<sup>st</sup> March 2024 being the balancing figures between audited figures in respect of the full financial year ended 31<sup>st</sup> March 2025/31<sup>st</sup> March 2024 and the published un-audited year to date figures



up to the end of the third quarter of the relevant financial year, which was subjected to a limited review by us, as required under the Listing Regulations.

Our opinion on the statement in respect of the above stated matter is not modified.

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N



(CA. Rohit Mehra)  
Partner

Membership No. 093910



UDIN: 25093910 B M I U E M 4996

Place: Noida

Date: 26<sup>th</sup> May, 2025

## YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: [www.yatharthhospitals.com](http://www.yatharthhospitals.com)

Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

CIN : L85110DL2008PLC174706

### STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH, 2025

(Rs. in Million except Shares and EPS)

	Particulars	Standalone				
		Quarter Ended		Year Ended		
		31-Mar-25 Audited#	31-Dec-24 Unaudited	31-Mar-24 Audited#	31-Mar-25 Audited	31-Mar-24 Audited
<b>I</b>	Revenue from operations	1,119.92	1,104.11	1,055.93	4,542.41	4,197.91
<b>II</b>	Other income	40.98	31.54	50.57	116.93	135.54
<b>III</b>	<b>Total Income (I+II)</b>	<b>1,160.90</b>	<b>1,135.66</b>	<b>1,106.50</b>	<b>4,659.33</b>	<b>4,333.44</b>
<b>IV</b>	<b>Expenses</b>					
	Medical consumables and pharmacy items consumed	231.83	196.68	204.15	878.86	788.56
	Employee benefits expense	213.91	208.81	190.35	823.89	726.02
	Finance costs	1.53	1.46	1.86	6.16	43.05
	Depreciation and amortisation	47.09	51.85	31.46	186.63	134.45
	Other expenses	356.43	380.64	385.49	1,569.48	1,510.22
	<b>Total expenses (IV)</b>	<b>850.78</b>	<b>839.44</b>	<b>813.31</b>	<b>3,465.02</b>	<b>3,202.30</b>
<b>V</b>	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>310.12</b>	<b>296.22</b>	<b>293.20</b>	<b>1,194.31</b>	<b>1,131.15</b>
<b>VI</b>	Exceptional items (net)(Gain)/Loss	-	-	-	-	-
<b>VII</b>	<b>Profit / (loss) before tax (V-VI)</b>	<b>310.12</b>	<b>296.22</b>	<b>293.20</b>	<b>1,194.31</b>	<b>1,131.15</b>
<b>VIII</b>	Tax expense					
	(1) Current tax	89.50	74.99	25.52	314.91	293.29
	(2) MAT credit entitlement	-	-	-	-	-
	(2) Income tax of earlier years	-	-	-	(0.21)	-
	(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-	-
	(4) Deferred tax	1.67	(1.31)	5.28	2.69	(2.08)
	<b>Total tax (VIII)</b>	<b>91.16</b>	<b>73.68</b>	<b>30.80</b>	<b>317.39</b>	<b>291.21</b>
<b>IX</b>	<b>Net Profit/(loss) after tax (VII-VIII)</b>	<b>218.96</b>	<b>222.53</b>	<b>262.39</b>	<b>876.92</b>	<b>839.94</b>
<b>X</b>	<b>Other Comprehensive Income</b>					
	A (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
	B (i) Items that will not be reclassified to profit or loss	2.06	1.20	1.28	2.20	1.28
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.52)	(0.30)	(0.32)	(0.55)	(0.32)
	<b>Other comprehensive income for the period</b>	<b>1.54</b>	<b>0.90</b>	<b>0.95</b>	<b>1.65</b>	<b>0.95</b>
<b>XI</b>	<b>Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b>	<b>220.50</b>	<b>223.43</b>	<b>263.35</b>	<b>878.57</b>	<b>840.89</b>
<b>XII</b>	<b>Other equity</b>				<b>14,287.90</b>	<b>7,511.39</b>
<b>XIII</b>	<b>Earnings Per Share (Rs. 10 each)</b>					
	(Not annualised except for the year ended 31 March 2024)					
	Basic	2.55	2.60	3.32	9.89	10.61
	Diluted	2.55	2.60	3.32	9.89	10.61
	Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	<b>963.54</b>	<b>963.54</b>	<b>858.50</b>	<b>963.54</b>	<b>858.50</b>

EPS is calculated based on Weighted Average Number of Shares for quarter ended 31st December, 2024, 31st March, 2025 and year ended 31st March, 2025.



**YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED**  
**STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2025**  
(all amounts in Rs. millions, unless otherwise stated)

Particulars	Figures for the year ended March 31, 2025	Figures for the year ended March 31, 2024
<b>A. Cash flow from operating activities</b>		
Profit before tax and exceptional items	1,194.31	1,131.15
<u>Adjustments for:</u>		
Depreciation and Amortisation expense	186.63	134.45
Finance costs	6.16	43.05
Interest on Bank deposits	(62.70)	(118.39)
Loss/(Gain) on redemption & Fair Value of Investments	(28.91)	-
<b>Operating profit before working capital changes</b>	<b>1,295.51</b>	<b>1,190.25</b>
<b>Working capital adjustments</b>		
(Increase)/Decrease in Trade receivables	(273.05)	(576.27)
(Increase)/Decrease in Inventories	(53.63)	(7.07)
(Increase)/Decrease in Financial Assets and other Current and Non-Current Assets	58.93	(126.62)
Increase (Decrease) in Financial Liabilities & Other Current and Non-Current Liabilities	(20.76)	28.99
Increase (Decrease) in Short Term and Long Term Provisions	10.41	8.37
<b>Cash generated from operations</b>	<b>1,017.40</b>	<b>517.64</b>
Income tax (paid)/Refund (net)	(130.57)	(358.02)
<b>Net cash inflow from (used in) operating activities-----'A'</b>	<b>886.83</b>	<b>159.63</b>
<b>B. Cash flow from Investing activities</b>		
Purchase of Property, plant and equipment including capital work in progress and capital advances and capital creditors	(2,049.40)	(340.08)
Investment in Subsidiary	(925.45)	(201.06)
Interest on Bank deposits	62.70	118.39
Investment in bank deposits having original maturity of more than three months	650.62	(1,251.97)
Investment in shares & mutual funds	(744.95)	-
Gain/(Loss) on redemption & Fair Value of investments	28.91	-
<b>Net cash used in investing activities-----'B'</b>	<b>(2,977.57)</b>	<b>(1,674.72)</b>
<b>C. Cash flow from Financing activities</b>		
Issue of share including premium (net of issue expenses)	6,002.99	5,767.72
Payment of loans to subsidiary company's	(2,554.26)	(2,197.41)
Interest & financial charges paid	(6.16)	(43.05)
Net Movement of Long Term Borrowings and short term borrowings	(35.33)	(1,100.96)
Payment of lease liability	58.96	(20.45)
<b>Net cash used in financing activities----'C'</b>	<b>3,466.20</b>	<b>2,405.85</b>
Net increase/(Decrease) in cash or cash equivalent (A+B+C)	1,375.46	890.75
Cash & cash equivalent at the commencement of the period	1,012.30	121.55
<b>Cash &amp; cash equivalent at the end of the period</b>	<b>2,387.76</b>	<b>1,012.30</b>
Reconciliation of cash and cash equivalents as per the cash flow statement		
Balance with banks in current accounts	791.04	739.15
Cash in hand	44.12	12.16
Bank Deposits with maturing within 3 months- pledged with banks	1,552.60	260.99
<b>Total</b>	<b>2,387.76</b>	<b>1,012.30</b>



*Asst*

**YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED**

CIN:U85110DL2008PLC174706

**STANDALONE BALANCE SHEET AS AT MARCH 31,2025**

(all amounts in Rs. millions, unless otherwise stated)

Particulars	Figures as at March 31, 2025	Figures as at March 31, 2024
<b>ASSETS</b>		
<b>I Non-current assets</b>		
(a) Property, Plant and Equipment	1,537.78	1,311.10
(b) Capital work in progress	1,533.65	-
(c) Right-of-use of assets	73.59	14.06
(d) Financial Assets		
(i) Investments	1,598.06	669.89
(ii) Other Financial Assets	91.65	59.40
(e) Other Non Current Assets	119.27	93.19
<b>Total non-current assets</b>	<b>4,954.01</b>	<b>2,147.64</b>
<b>II Current assets</b>		
(a) Inventories	92.90	39.27
(b) Financial Assets		
(i) Current Investments	742.23	-
(ii) Trade receivables	1,707.60	1,434.54
(iii) Cash and cash equivalents	2,387.76	1,012.30
(iv) Bank Balance other than (iii) above	607.17	1,257.79
(v) Other Financial Assets	5,162.05	2,607.79
(c) Current Tax assets (Net)	-	122.00
(d) Other Current assets	92.78	162.52
<b>Total current assets</b>	<b>10,792.48</b>	<b>6,636.22</b>
<b>Total Assets</b>	<b>15,746.49</b>	<b>8,783.86</b>
<b>EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Equity Share Capital	963.54	858.50
(b) Other Equity	14,287.90	7,511.39
<b>Equity attributable to the owners of the company</b>	<b>15,251.45</b>	<b>8,369.89</b>
<b>II Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	-	20.28
(ia) Lease Liabilities	43.61	-
(b) Provisions	24.82	16.82
(c) Deferred tax liabilities (Net)	44.46	41.21
<b>Total non-current liabilities</b>	<b>112.88</b>	<b>78.31</b>
<b>III Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	-	15.05
(ia) Lease Liabilities	31.26	15.91
(ii) Trade payables		
(a) Total outstanding dues of Micro Enterprises and Small Enterprises	45.77	62.83
(b) Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	60.88	53.31
(iii) Other financial liabilities	152.84	173.43
(b) Other current liabilities	23.98	14.66
(c) Provisions	67.44	0.47
<b>Total current liabilities</b>	<b>382.16</b>	<b>335.66</b>
<b>Total Equity and Liabilities</b>	<b>15,746.49</b>	<b>8,783.86</b>



**Notes to accounts on the audited standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the Quarter and Financial Year ended March 31<sup>st</sup>, 2025:**

1. The audited standalone financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited for the Quarter and year ended March 31<sup>st</sup>, 2025, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 26<sup>th</sup>, 2025.
2. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
3. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
4. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any significant tax liability on the Company.

Also the department had ordered for provisional attachment under Section 281B of the IT Act, of (i) 20,714,727 unquoted equity shares of face value ₹10 each of AKS; (ii) 5,622,950 unquoted equity shares of face value ₹10 of Sanskar Medica India Limited; (iii) 4,010,000 unquoted equity shares of face value ₹10 of Ramraja; and (iv) 45,000,980 unquoted equity shares of face value ₹10 of Pristine Infracon Private Limited, held by our Company and group properties located at (a) Plot No. NH 32, Sector Omega I, Greater Noida, Uttar Pradesh, India; (b) NH-01, Sector 110, Noida, Gautam Budh Nagar, Uttar Pradesh, India; (c) Jhansi Mauranipur Highway, Near Orchha Tigaila Orchha, Tikamgarh, Pratap Pura, Madhya Pradesh; and (d) Plot No. HO-01, Sector 1, Greater Noida (West), Uttar Pradesh, India and prohibited the holder/ owner from transferring/ parting with such property from the date of such respective orders in order to protect its interest.

5. During the previous year FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.



The utilization of the IPO is summarized below:

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in Rs. Million			
			As at beginning of the quarter	During the quarter	At the end of the quarter	Balance as on 31.03.2025
1	Repayment, in full or part, of certain borrowings availed by the company	1000.00	1,000.00	-	1,000.00	-
2	Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja	1450.00	1,427.20	-	1,427.20	22.80
3	Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital	256.40	256.40	-	256.40	-
4	Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them	1069.70	562.97	-	562.97	506.73
5	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	650.00	-	650.00	-
6	General Corporate Purpose	1271.00	1,234.43	-	1,234.43	36.57
	<b>Total</b>	<b>5697.10</b>	<b>5,131.00</b>	<b>-</b>	<b>5,131.00</b>	<b>566.10</b>

6. During the current financial year FY 2024-25, the Company raised further funds from Qualified Institutional buyers (QIB) in qualified institutional placements. In QIP Fresh issue of 105,04,124 Equity Shares issued at a price of Rs. 595/- for amount aggregating to ₹ 6249.95 million by our Company ("Fresh Issue").



The utilization of the QIP is summarized below:

(amount in million)

Object(s)	Amount as per final offer document	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at 31.03.2025
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by: Company and Subsidiary	956.80	-	956.80	956.80	Nil
Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana	2173.85	1139.49	876.38	2015.88	157.97
Funding for purchase of medical equipment's	1517.36	-	47.10	47.10	1470.26
General corporate purposes	1390.99	-	659.85	659.85	731.14
Sub-total	6039.00	1139.49	2540.14	3679.63	2359.37
Issue expenses	210.95	94.30	116.65	210.95	-
Total proceeds from QIP	<b>6249.95</b>	<b>1233.79</b>	<b>2656.79</b>	<b>3890.58</b>	<b>2359.37</b>



*Asst*

7. The Company had participated in an e-auction under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act of 2002 (“SARFAESI Act”) conducted by Union Bank of India on October 29, 2024, for purchase of (i) a leasehold land building, which is a hospital located at Plot No. 4C, Institutional Area, Model Town - III, Shahid Ram Prasad Bismil Marg Delhi 110009, India, admeasuring to 8,000 square meters, comprising of four-story hospital building with two basement floors; and (ii) hypothecated plant and machinery present inside the hospital premises as movable and immovable item, under *pari passu* charge with Union Bank of India (collectively “Scheduled Property”). Subsequently, the sale confirmation letter dated October 30, 2024 was issued by Union Bank of India to our Company.

Accordingly, Company had paid entire Sale Consideration in permitted trenches. The final letter was received from Union Bank of India on 15.03.2025 and the registration of property has been done on 28<sup>th</sup> March 2025. The company hopes to commence commercial operations soon.

8. The Company had entered into a strategic collaboration agreement to acquire 60% equity shareholding for ₹912.00 million (“Purchase consideration”) in MGS Infotech Research and Solutions Private Limited (“MGS”), on a going concern basis, along with transfer of all rights and interest by the existing shareholders towards assets (including fixed assets and current assets) and liabilities in a hospital in Faridabad, Haryana, with an enterprise value of ₹1,520.00 million having capacity of over 400 beds. The company has entered into the share purchase agreement and has acquired 60% in MGS. Accordingly MGS has become a subsidiary of the company. The company hopes to commence commercial operations soon.
9. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable
10. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).

**On behalf of the Board of Directors**  
**Yatharth Hospital & Trauma Care Services Ltd.**  
**Dr. Ajay Kumar Tyagi**


**Chairman and Whole-time Director**  
**Place: Greater Noida**  
**Dated: 26/05/2025**





**R. NAGPAL ASSOCIATES**  
CHARTERED ACCOUNTANTS

B-1/1018, VASANT KUNJ,  
NEW DELHI - 110 070  
TELEPHONE : 011-41082626  
EMAIL : rohit\_mehra@rnaca.in  
rnaca1@gmail.com

**Independent Auditor's Report On Annual Audited Ind AS Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited for the quarter and year ended March 31, 2025 pursuant to Regulations 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited

Report on the Audit of Consolidated Financial Results

We have audited the accompanying statement containing the Annual Consolidated Audited financial results of **Yatharth Hospital & Trauma Care Services Limited** (hereinafter referred to as "the Holding Company ") and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "the Group") for the Quarter and year ended 31st March, 2025 together with the notes thereon (hereinafter referred to as "the Statement") being submitted by the Holding Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statement/financial information of subsidiaries referred in other matters section below, the statement

- a) Includes the result of the following entities:
  - (i) AKS Medical & Research Centre Private Limited
  - (ii) Ramraja Multispeciality Hospital & Trauma Centre Private Limited
  - (iii) Sanskar Medica India Limited
  - (iv) Pristine Infracon Private Limited.
  - (v) MGS Infotech Research and Solutions Private Limited.
- b) is presented in accordance with the requirements of Regulations 33 of the Listing Regulations; and
- c) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the total comprehensive income (comprising of profit and other comprehensive income) and other financial information of the Group for the Quarter and year ended March 31, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in Auditor's Responsibilities for the Audit of the statement section of our report. We are independent of the Holding Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical



requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Responsibilities of the Management and Those Charged with Governance for this Statement**

This accompanying Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors has been prepared on the basis of the related Consolidated annual financial statement. The Board of Directors of the Holding Company are responsible for the preparation and presentation of the statement that give a true and fair view of the net profit and other comprehensive income of the group and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (IND AS) prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error, which have been used for the purpose of the statement by the management of the Holding Company, as aforesaid.

In preparing the accompanying Statement, the Board of Directors of the Companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective company's management and Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one



resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on complete set of financial statement on whether the company has adequate internal financial control with reference to financial statement in place and the operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related made by the Board of Directors
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Annual Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statements represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the statement of which we are the independent auditors. For the other entities included in the statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibility in this regard are further described in para (1) of the section titled "Other Matters" in this audit report.

Materiality is the magnitude or misstatements in the Annual Consolidated Financial Results that individually or In aggregate, makes it probable that the economic decision of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We Consider quantitative materiality and qualitative factors (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Holding Company and such other entities included in the statement of which we are the independent auditors regarding, among



other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed the procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to extent applicable.

#### **Other Matters**

- a) We did not audit the audited financial results of five subsidiaries whose financial statements reflect total assets of Rs. 7419.96 Millions as at 31<sup>st</sup> March, 2025 Total revenues of Rs.1213.43 Millions and 4326.67 Millions, total Net Profit after tax of Rs. 167.77 Millions and Rs. 428.08 Millions, total comprehensive income of Rs. 168.39 Millions and Rs.429.36 Millions for the for the quarter and year ended 31<sup>st</sup> March 2025 respectively, and net cash inflow of Rs. 1210.48 Millions for the year ended 31<sup>st</sup> March, 2025 as considered in the statement, which have been audited by their respective independent auditors.


The Independent auditor's report on the financial results of these entities have been furnished to us and our opinion on the statement, in no far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph above.

Our opinion on the statement in respect of the above stated matter is not modified.

- b) Attention is drawn to the fact that the figures for the quarter ended 31<sup>st</sup> March 2025 and 31<sup>st</sup> March 2024 being the balancing figures between audited figures in respect of the full financial year ended 31<sup>st</sup> March 2025/31<sup>st</sup> March 2024 and the published un-audited year to date figures up to the end of the third quarter of the relevant financial year, which was subjected to a limited review by us, as required under the Listing Regulations.

Our opinion on the statement in respect of the above stated matter is not modified.

**For R. Nagpal Associates**  
**Chartered Accountants**  
**Firm Registration No. 002626N**

  
**(CA. Rohit Mehra)**  
**Partner**  
**Membership No. 093910**



**UDIN: 25093910BMIUEN6374**  
**Place: Noida**  
**Date: 26<sup>th</sup> May, 2025**

**YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED**  
**Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India**

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: cs@yatharthhospitals.com

CIN : L85110DL2008PLC174706

**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH, 2025**

(Rs. in Million except Shares and EPS)

Particulars	Consolidated				
	Quarter Ended		Year Ended		
	31-Mar-25 Audited#	31-Dec-24 Unaudited	31-Mar-24 Audited#	31-Mar-25 Audited	31-Mar-24 Audited
<b>I</b> Revenue from operations	2,317.81	2,191.55	1,777.53	8,804.87	6,705.47
<b>II</b> Other income	53.41	42.10	56.56	161.75	156.10
<b>III Total Income (I+II)</b>	<b>2,371.22</b>	<b>2,233.65</b>	<b>1,834.09</b>	<b>8,966.62</b>	<b>6,861.58</b>
<b>IV Expenses</b>					
Medical consumables and pharmacy items consumed	464.97	420.63	374.75	1,785.29	1,333.11
Employee benefits expense	438.20	426.15	318.67	1,625.00	1,170.23
Finance costs	9.72	20.58	3.80	75.11	94.18
Depreciation and amortisation	128.70	169.13	76.96	571.72	293.00
Other expenses	844.32	795.60	618.79	3,192.11	2,402.74
<b>Total expenses (IV)</b>	<b>1,885.91</b>	<b>1,832.09</b>	<b>1,392.97</b>	<b>7,249.22</b>	<b>5,293.26</b>
<b>V Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>485.31</b>	<b>401.56</b>	<b>441.12</b>	<b>1,717.39</b>	<b>1,568.32</b>
<b>VI Exceptional items (net)(Gain)/Loss</b>	-	-	-	-	-
<b>VII Profit / (loss) before tax (V-VI)</b>	<b>485.31</b>	<b>401.56</b>	<b>441.12</b>	<b>1,717.39</b>	<b>1,568.32</b>
<b>VIII Tax expense</b>					
(1) Current tax	137.55	112.05	42.90	491.62	402.78
(2) MAT credit entitlement	-	-	0.01	(0.19)	0.01
(2) Income tax of earlier years	-	-	-	-	4.88
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-	15.91
(4) Deferred tax	(39.47)	(15.40)	14.71	(79.54)	423.57
<b>Total tax (VIII)</b>	<b>98.08</b>	<b>96.64</b>	<b>57.62</b>	<b>411.89</b>	<b>423.57</b>
<b>IX Net Profit/(loss) after tax (VII-VIII)</b>	<b>387.23</b>	<b>304.91</b>	<b>383.49</b>	<b>1,305.50</b>	<b>1,144.75</b>
<b>X Other Comprehensive Income</b>					
A (i) Items that will be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
B (i) Items that will not be reclassified to profit or loss	2.88	2.47	1.52	3.91	1.52
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.72)	(0.62)	(0.39)	(0.98)	(0.39)
<b>Other comprehensive income for the period</b>	<b>2.16</b>	<b>1.85</b>	<b>1.13</b>	<b>2.93</b>	<b>1.13</b>
<b>XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b>	<b>389.39</b>	<b>306.76</b>	<b>384.62</b>	<b>1,308.43</b>	<b>1,145.87</b>
<b>Profit/(Loss) for the year attributable to:</b>					
To the Owners of the company	387.18	304.91	383.49	1,305.45	1,144.75
Non Controlling Interest	0.05	-	-	0.05	-
<b>Other comprehensive income for the period/year attributable to:</b>					
To the Owners of the company	2.16	1.85	1.13	2.93	1.13
Non Controlling Interest	-	-	-	-	-
<b>Total Comprehensive Income for the period attributable to:</b>					
To the Owners of the company	389.34	306.76	384.62	1,308.38	1,145.87
Non Controlling Interest	0.05	-	-	0.05	-
<b>XII Other equity</b>				<b>15,091.05</b>	<b>7,884.73</b>
<b>XIII Earnings Per Share (Rs.10 each)</b>					
(Not annualised except for the year ended 31 March 2024)					
Basic	4.37	3.57	4.85	14.72	14.46
Diluted	4.37	3.57	4.85	14.72	14.46
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	963.54	963.54	858.50	963.54	858.50

EPS is calculated based on Weighted Average Number of Shares for quarter ended 31st December, 2024, 31st March, 2025 and year ended 31st March, 2025.



*Handwritten signature*

**YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED**  
**Consolidated Statement of Assets & Liabilities as at March 31, 2025**

(All amounts in million, unless otherwise stated)

Particulars	As at March 31, 2025	As at March 31, 2024
<b>ASSETS</b>		
<b>I Non-current assets</b>		
(a) Property, Plant and Equipment	4,930.38	3,807.91
(b) Intangible Assets	-	-
(c) Capital work in progress	2,220.64	-
(d) Right-of-use of assets	73.59	14.06
(e) Goodwill	1,047.28	596.83
(f) Financial Assets		
(i) Investments	2.72	-
(i) Other Financial Assets	53.18	242.98
(g) Deferred Tax Assets (Net)	181.16	102.60
(h) Other Non Current Assets	245.52	326.45
<b>Total non-current assets</b>	<b>8,754.48</b>	<b>5,090.83</b>
<b>II Current assets</b>		
(a) Inventories	209.51	81.34
(b) Financial Assets		
(i) Current Investments	742.23	-
(ii) Trade receivables	3,015.05	2,270.03
(iii) Cash and cash equivalents	3,616.48	1,126.96
(iv) Bank Balance other than (iii) above	789.27	1,259.40
(c) Current Tax assets (Net)	32.01	146.49
(d) Other Current assets	152.72	218.25
<b>Total current assets</b>	<b>8,557.28</b>	<b>5,102.47</b>
<b>Total Assets</b>	<b>17,311.76</b>	<b>10,193.30</b>
<b>EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Equity Share Capital	963.54	858.50
(b) Other Equity	15,091.05	7,884.73
<b>Equity attributable to the owners of the company</b>	<b>16,054.60</b>	<b>8,743.23</b>
Non-controlling interest	316.71	-
<b>Total Equity</b>	<b>16,371.31</b>	<b>8,743.23</b>
<b>II Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	9.69	752.46
(ii) Lease Liabilities	43.61	-
(b) Provisions	41.38	25.40
(c) Deferred tax liabilities (Net)	-	-
<b>Total non-current liabilities</b>	<b>94.67</b>	<b>777.86</b>
<b>III Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	31.30	78.09
(ii) Lease Liabilities	31.26	15.91
(iii) Trade payables		
(a) Total outstanding dues of Micro Enterprises and Small Enterprises	124.53	125.24
(b) Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	166.83	166.37
(iv) Other financial liabilities	333.22	252.75
(b) Other current liabilities	46.69	33.34
(c) Provisions	111.94	0.51
<b>Total current liabilities</b>	<b>845.77</b>	<b>672.21</b>
<b>Total Equity and Liabilities</b>	<b>17,311.76</b>	<b>10,193.30</b>



*Aut*

**YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED**  
**Consolidated Statement of Cash Flow for the year ended March 31, 2025**

(All amounts in million, unless otherwise stated)

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax and exceptional items	1,717.39	1,568.32
<u>Adjustments for :</u>		
Depreciation and Amortisation expense	571.72	293.00
Finance costs	75.11	94.18
Interest on bank deposits	(78.04)	(125.34)
Loss/(Gain) on redemption & Fair Value of Investments	(28.91)	-
<b>Operating profit before working capital changes</b>	<b>2,257.26</b>	<b>1,830.15</b>
<b>Working capital adjustments</b>		
(Increase)/Decrease in Trade receivables	(745.03)	(1,192.48)
(Increase)/Decrease in Inventories	(128.17)	(19.13)
(Increase)/Decrease in Financial Assets and other Current and Non-Current Assets	271.35	(310.85)
Increase (Decrease) in Financial Liabilities & Other Current and Non-Current Liabilities	86.25	91.53
Increase (Decrease) in Current and Non current Provisions	20.33	7.49
<b>Cash generated from operations</b>	<b>1,761.99</b>	<b>406.71</b>
Income tax (paid)/Refund (net)	(265.97)	(437.49)
<b>Net cash inflow from operating activities----'A'</b>	<b>1,496.03</b>	<b>(30.78)</b>
<b>B. Cash flow from Investing activities</b>		
Purchase of Property, plant and equipment including capital work in progress and capital advances and capital creditors	(3,108.29)	(933.65)
Acquisition of Fixed Assets-Net of Liabilities On account of Business Combination	-	-
Investment in Subsidiary	(925.45)	(201.06)
Interest on Bank deposits	78.04	125.34
Investment in shares & mutual funds	(744.95)	-
Investment in bank deposits having original maturity of more than three months	470.14	(1,249.29)
Gain/(Loss) on redemption & Fair Value of investments	28.91	-
<b>Net cash used in investing activities-----'B'</b>	<b>(4,201.61)</b>	<b>(2,258.65)</b>
<b>C. Cash flow from Financing activities</b>		
Net movement of long term borrowings and short term borrowings	(732.90)	(2,631.47)
Finance Cost	(75.11)	(94.18)
Issue of share including premium net of share issue expenses	6,002.99	5,767.72
Payment of lease liability	-	-
<b>Net cash used in financing activities---'C'</b>	<b>5,194.98</b>	<b>3,042.07</b>
Net increase/(Decrease) in cash or cash equivalent (A+B+C)	2,489.40	752.64
Cash & cash equivalent at the commencement of the period	1,126.96	374.32
Add: On account of Business Combination	0.12	0.00
<b>Cash &amp; cash equivalent at the end of the period</b>	<b>3,616.48</b>	<b>1,126.96</b>
Reconciliation of cash and cash equivalents as per the cash flow statement		
Balance with banks in current accounts	1,867.75	843.32
Cash in hand	196.12	22.31
Bank Deposits with maturing with in 3 months- pledged with banks	1,552.60	261.33
<b>Total</b>	<b>3,616.48</b>	<b>1,126.96</b>



**Notes to accounts on the Audited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited for the Quarter and financial year ended March 31st, 2025:**

1. The audited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries for the Quarter and year ended March 31st, 2025, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 26<sup>th</sup>, 2025.
2. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
3. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
4. The Income Tax Department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any significant tax liability on the Company.

Also the department had ordered for provisional attachment under Section 281B of the IT Act, of (i) 20,714,727 unquoted equity shares of face value ₹10 each of AKS; (ii) 5,622,950 unquoted equity shares of face value ₹10 of Sanskar Medica India Limited; (iii) 4,010,000 unquoted equity shares of face value ₹10 of Ramraja; and (iv) 45,000,980 unquoted equity shares of face value ₹10 of Pristine Infracon Private Limited, held by our Company and group properties located at (a) Plot No. NH 32, Sector Omega I, Greater Noida, Uttar Pradesh, India; (b) NH-01, Sector 110, Noida, Gautam Budh Nagar, Uttar Pradesh, India; (c) Jhansi Mauranipur Highway, Near Orchha Tigaila Orchha, Tikamgarh, Pratap Pura, Madhya Pradesh; and (d) Plot No. HO-01, Sector 1, Greater Noida (West), Uttar Pradesh, India and prohibited the holder/ owner from transferring/ parting with such property from the date of such respective orders in order to protect its interest.

The subsidiary group, i.e AKS Medical & Research Centre Private Limited, has revised its ITR in response to notice under section 148 of the Income Tax act for assessment year 2021-22 & 22-23 and has deposited a sum of Rs 5.00 million & 7.38 million as additional tax on 29<sup>th</sup> April 2025.

5. During the previous year FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.



The utilization of the IPO is summarized below:

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in Rs. Million			
			As at beginning of the quarter	During the quarter	At the end of the quarter	Balance as on 31.03.2025
1	Repayment, in full or part, of certain borrowings availed by the company	1000.00	1,000.00	-	1,000.00	-
2	Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja	1450.00	1,427.20	-	1,427.20	22.80
3	Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital	256.40	256.40	-	256.40	-
4	Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them	1069.70	562.97	-	562.97	506.73
5	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	650.00	-	650.00	-
6	General Corporate Purpose	1271.00	1,234.43	-	1,234.43	36.57
	<b>Total</b>	<b>5697.10</b>	<b>5,131.00</b>	<b>-</b>	<b>5,131.00</b>	<b>566.10</b>

6. During the current financial year FY 2024-25, the Company raised further funds from Qualified Institutional buyers (QIB) in qualified institutional placements. In QIP fresh issue of 105,04,124 Equity Shares issued at a price of 595.00 per equity share for amount aggregating to ₹ 6249.95 million by our Company ("Fresh Issue").



The utilization of the QIP is summarized below:

Object(s)	Amount as per final offer document	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at 31.03.2025
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by: Company and Subsidiary	956.80	-	956.80	956.80	Nil
Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana	2173.85	1139.49	876.38	2015.88	157.97
Funding for purchase of medical equipment's	1517.36	-	47.10	47.10	1470.26
General corporate purposes	1390.99	-	659.85	659.85	731.14
Sub-total	6039.00	1139.49	2540.14	3679.63	2359.37
Issue expenses	210.95	94.30	116.65	210.95	-
<b>Total</b>	<b>6249.95</b>	<b>1233.79</b>	<b>2656.79</b>	<b>3890.58</b>	<b>2359.37</b>

7. The Company had participated in an e-auction under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act of 2002 ("SARFAESI Act") conducted by Union Bank of India on October 29, 2024, for purchase of (i) a leasehold land building, which is a hospital located at Plot No. 4C, Institutional Area, Model Town - III, Shahid Ram Prasad Bismil Marg Delhi 110009, India, admeasuring to 8,000 square meters, comprising of four-story hospital building with two basement floors; and (ii) hypothecated plant and machinery present inside the hospital premises as movable and immovable item, under *pari passu* charge with Union Bank of India (collectively "Scheduled Property"). Subsequently, the sale confirmation letter dated October 30, 2024 was issued by Union Bank of India to our Company.

Accordingly, Company had paid entire Sale Consideration in permitted trenches. The final letter was received from Union Bank of India on 15.03.2025 and the registration of property has been done on 28<sup>th</sup> March 2025. The company hopes to commence commercial operations soon.



8. The Company had entered into a strategic collaboration agreement to acquire 60% equity shareholding for ₹912.00 million (“ Purchase consideration”) in MGS Infotech Research and Solutions Private Limited (“MGS”), on a going concern basis, along with transfer of all rights and interest by the existing shareholders towards assets (including fixed assets and current assets) and liabilities in a hospital in Faridabad, Haryana, with an enterprise value of ₹1,520.00 million having capacity of over 400 beds. The company has entered into the share purchase agreement and has acquired 60% in MGS. Accordingly MGS has become a subsidiary of the company. The company hopes to commence the commercial operations soon.
9. In respect of subsidiary company i.e. Ramraja Hospital & Trauma Centre Pvt Ltd. an order from Divisional Commissioner of Sagar, Madhya Pradesh was received to take over the hospital premises, as the land stated in the order belonged to the State of Madhya Pradesh. In respect of the writ petition filed by the company, the honorable high court of Madhya Pradesh, has set aside the order passed by the divisional commissioner of Sagar and the company was directed to appear before the commissioner Sagar on 11<sup>th</sup> November 2024. The company has adhered to the direction of the court and proceeding is going on and expects a positive outcome out of it.
10. In respect of subsidiary company i.e Pristine Infratech Pvt Limited which was acquired on 28<sup>th</sup> March 2024 and resumed operations of the hospital w.e.f. 12<sup>th</sup> May 2024. There has been non-compliance towards filing of income tax return for the financial year ended March 31, 2023 by the erstwhile promoters. The Company after acquisition had undergone necessary compliance and filed tax audit report with the Income Tax Department and its application for condonation of delay has been filed with the respective authorities. There after all compliance are being made.
11. The figures for the quarter ended 31<sup>st</sup> March 2025 and 31<sup>st</sup> March 2024 are the balancing figures between audited figures in respect of full financial years and unaudited year to date figures upto 31<sup>st</sup> December 2024 and 31<sup>st</sup> December 2023 respectively. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable.
12. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) ).

**On behalf of the Board of Directors**

**Yatharth Hospital & Trauma Care Service Ltd**

  
**Dr. Ajay Kumar Tyagi**  
**Chairman and Whole-time Director**

**Place: Greater Noida**

**Dated: 26/05/2025**



# Yatharth Hospital and Trauma Care Services Limited

CIN No.: L85110DL2008PLC174706

YH/SE/2025-26  
May 26, 2025

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor, Plot No. C/1  
G Block, Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051, India  
Symbol: YATHARTH  
ISIN: INE0JO301016

Dept. of Listing Operations  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001, India  
Scrip Code: 543950  
ISIN: INE0JO301016

**Subject: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Audit Report with unmodified opinion.**

Dear Sir/Madam,

Pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that M/s. **R. Nagpal Associates**, Chartered Accountants, (FRN: 002626N), Statutory Auditors of the Company, have issued an Audit Report with unmodified opinion on Audited Financial Results (Consolidated and Standalone) of the Company for the fourth quarter and financial year ended March 31, 2025.

This is for your kind information and records.

Thanking You

Yours Faithfully,  
For Yatharth Hospital and Trauma Care Services Limited

  
Pankaj Prabhakar  
Chief Financial Officer



## Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025  
Tel: 011-49967892

## Corporate Office

HO-01, Sector-01, Greater Noida West-201306  
Tel: 0120-6811236 | Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

## Our Hospitals

- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 🌐 [www.yatharthhospitals.com](http://www.yatharthhospitals.com)